Izokibep
As of the edition of 20 October 2026, Izokibep is a protein: stopped in 2025; acts on IL17A.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2025
- Kind
- Protein
- Registered trials
- 9, 4 stopped early
- Disease areas
- Skin and connective tissue; Bones, joints and muscles; Eye; Infections
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route A because of this drug.
Companies on route A for this drug
In the product2 companies are on route A because of Izokibep.
See the 2 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| IL17A | Interleukin-17A | Q16552 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 6 | 4 | 0 | 2 |
| Phase 3 | 2 | 0 | 0 | 2 |
| All trials | 9 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Affibody | Lead sponsor of trials | 2016 to now |
| Alumis | Lead sponsor of trials | 2020 to now |
| Ikena Oncology | Lead sponsor of trials | 2021 to now |